Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Fovista in Combination with Anti-VEGF Agents for Wet AMD
NCT02387957Phase 2Terminated
- Sponsor
- IVERIC bio
- Start
- Apr 2016
- Primary completion
- Jan 2017
- Modality
- Polymer-based Nanoparticles, RNA Aptamers, DNA Aptamers
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pegpleranib in age-related macular degeneration (AMD) (3 arms), sponsored by IVERIC bio. Primary endpoints: Total Number of Systemic Adverse Events at 2 years and Total Number of Other Adverse Events (>5%) at 2 years. Started Apr 2016; status: terminated.
02
Drugs
pegpleranib
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT02387957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02387957.